Serum level of (interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-α), motilin (MTL), gastrin (GAS), pepsinogen (PG), after Adjunctive Treatment in Patients with Chronic Atrophic Gastritis
Serum level of (interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-α), motilin (MTL), gastrin (GAS), pepsinogen (PG),
Abstract
Introduction: it was to demonstrate the impact of traditional Chinese medicine (TCM) matrine combined with omeprazole enteric-coated tablets on the gastric mucosal histopathology, gastric function, inflammatory cytokines, and Helicobacter pylori (H. pylori) eradication in patients with chronic atrophic gastritis (CAG). Materials and Methods: a retrospective collection of case data from 110 patients with CAG admitted to the TCM Department of the hospital was conducted. Patients were rolled into test group (TG, matrine + omeprazole enteric-coated tablets) and control group (CG, omeprazole enteric-coated tablets). The gastric mucosal histopathological scores, serological indicators (interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-α), gastric function (motilin (MTL), gastrin (GAS), pepsinogen (PG)), H. pylori eradication rate, and clinical efficacy were compared. Results: the degree of glandular atrophy, intestinal metaplasia, dysplasia, and inflammatory activity index in patients of TG post-treatment were lower than CG (P<0.05). Post-treatment, IL-2, IL-10, and TNF-α levels in patients of TG were inferior to CG (P<0.05), and H. pylori eradication rate in patients of TG (87.27%) was inferior to CG (63.64%) (P<0.05). The effective treatment rate in patients of TG post-treatment (92.73%) was higher than CG (78.18%) (P<0.05). Conclusion:matrine plus omeprazole enteric-coated tablets can effectively improve gastric tissue-related symptoms in patients, increase the H. pylori eradication rate, and demonstrate a more significant clinical efficacy in the treatment of CAG compared to monotherapy with Western medicine alone.
References
Chen, H.F., Gong, Y., Huang, Z., Zhao, G., Chen, Z.M., Zen, Y.M., Li, H.Z. and Hu, Y.L., 2022. Efficacy and safety of Chinese herbal medicine QiruiWeishu capsule in treating chronic non-atrophic gastritis: A multicentre, double-blind, randomized controlled clinical trial. J.Ethnopharmacol.,294:115341. https://doi.org/ 10.1016/j.jep.2022.115341
Coles, M., Madray, V., Cox, K., Uy, P. and Sharma, A., 2020. More than just a hole in the wall: evolving management and treatment paradigms of suppurative gastritis. Dig. Dis. Sci.,65(8): 2203-2209. https://doi.org/10.1007/s10620-020-06356-6
Conti, L., Galli, G., Ligato, C., Carabotti, M., Annibale, B., Lahner, E. 2023. Autoimmune atrophic gastritis and coeliac disease: A case-control study. Dig Liver Dis. 55(1):69-74. doi: 10.1016/j.dld.2022.07.001. Epub 2022 Jul 27. PMID: 35906165.
Engiles, J.B., Uzal, F.A., Navarro, M.A., Reef, V.B. and Bender, S.J., 2022. Phlegmonous gastritis in 2 yearling horses. J. Vet.Diagn. Invest.,34(3): 429-438. https://doi.org/10.1177/10406387211065044
Ford, D.J. and Dingwall, A.K., 2019. Corrigendum to “The cancer COMPASS: Navigating the functions of MLL complexes in cancer” [Cancer Genetics 208 (2015) pp. 178-191]. Cancer Genet.,233-234:102. https://doi.org/10.1016/j.cancergen.2019.03.003
Illan Montero, J., Viala, J., Rebeuh, J., Berthet, S., Blais, R., Caldari, D., Lasfargue, M., Henaff, G.L., Mas, E., Rustom-Pecciarini, N., Berrebi, D., Henno, S. and Dabadie, A., 2023. Collagenous gastritis in children: A national cohort. Arch.Pediatr.,30(5): 307-313. https://doi.org/10.1016/j.arcped.2023.03.013
Kluger, N., Mähönen, K., Aitkoski, A., Hiltunen, E., Pankakoski, A., Panelius, J. and Lappalainen, K., 2020. Bullous pemphigoid-associated chronic atrophic gastritis. Dermatol. Ther.,33(4): e13671.https://doi.org/10.1111/dth.13671
Lim, N.R. and Chung, W.C., 2023. Helicobacter pylori-associated chronic atrophic gastritis and progression of gastric carcinogenesis. Korean J. Gastroenterol.,82(4): 171-179.https://doi.org/10.4166/kjg.2023.097
Liu, S., Shu, L., Yang, J., Liu, Y., Zhang, S., Wang, N. and Shi, Z., 2023. Rhein exhibits anti-inflammatory effects in chronic atrophic gastritis via Nrf2 and MAPK signaling. Turk. J. Gastroenterol.,34(5): 525-532.https://doi.org/10.5152/tjg.2023.22251
Luo, J., Cao, S., Ding, N., Liao, X., Peng, L. and Xu, C., 2022. A deep learning method to assist with chronic atrophic gastritis diagnosis using white light images. Dig. Liver Dis.,54(11): 1513-1519.https://doi.org/10.1016/j.dld.2022.04.025
Luo, W., Li, Y., Luo, Z. and Xu, B., 2020. Chronic atrophic gastritis aggravate chronic periodontitis with Helicobacter pylori infection and CD4+Th cytokines infiltration. Histol.Histopathol.,35(7): 665-672. https://doi.org/10.14670/HH-18-187
Massironi, S., Zilli, A., Elvevi, A. and Invernizzi, P., 2019. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmun. Rev.,18(3): 215-222.https://doi.org/10.1016/j.autrev.2018.08.011
Namekata, T., Miki, K., Kimmey, M., Fritsche, T., Hughes, D., Moore, D. and Suzuki, K., 2000. Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle. Am. J. Epidemiol.,151(8): 820-30.https://doi.org/10.1093/oxfordjournals.aje.a010282
Ou, L., Liu, H.R., Shi, X.Y., Peng, C., Zou, Y.J., Jia, J.W., Li, H., Zhu, Z.X., Wang, Y.H., Su, B.M., Lai, Y.Q., Chen, M.Y., Zhu, W.X., Feng, Z., Zhang, G.M. and Yao, M.C., 2024. Terminalia chebula Retz. aqueous extract inhibits the Helicobacter pylori-induced inflammatory response by regulating the inflammasome signaling and ER-stress pathway. J.Ethnopharmacol.,320:117428.https://doi.org/10.1016/j.jep.2023.117428
Peng, C., Feng, Z., Ou, L., Zou, Y., Sang, S., Liu, H., Zhu, W., Gan, G., Zhang, G. and Yao, M., 2023.Syzygium aromaticum enhances innate immunity by triggering macrophage M1 polarization and alleviates Helicobacter pylori-induced inflammation. J.Funct. Food.,107:105626. https://doi.org/10.1016/j.jff.2023.105626
Rao, W., Xie, M., Zang, Y.J. and Zhi, K.Q., 2021. Chronic atrophic gastritis and Helicobacter pylori infection status in liver transplant recipients. Transpl. Infect. Dis.,23(3): e13513.https://doi.org/10.1111/tid.13513
Shah, S.C., Piazuelo, M.B., Kuipers, E.J. and Li, D., 2021. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology,161(4): 1325-1332.e7.https://doi.org/10.1053/j.gastro.2021.06.078
Tan, B., Luo, H.Q., Xu, H., Lv, N.H., Shi, R.H., Luo, H.S., Li, J.S., Ren, J.L., Zou, Y.Y., Li, Y.Q., Ji, F., Fang, J.Y. and Qian, J.M., 2017.Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One,12(4): e0175625.https://doi.org/10.1371/journal.pone.0175625
Wang, L., Lin, Z., Chen, S., Li, J., Chen, C., Huang, Z., Ye, B., Ding, J., Li, W., Wu, L., Jiang, Y., Meng, L., Du, Q. and Si, J., 2017. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clin.Microbiol. Infect.,23(6): 391-395.https://doi.org/10.1016/j.cmi.2016.12.032
Weng, J., Wu, X.F., Shao, P., Liu, X.P. and Wang, C.X., 2023. Medicine for chronic atrophic gastritis: a systematic review, meta- and network pharmacology analysis. Ann. Med.,55(2): 2299352.https://doi.org/10.1080/07853890.2023.2299352
Yang, H., Zhou, X. and Hu, B., 2022. The ‘reversibility’ of chronic atrophic gastritis after the eradication of Helicobacter pylori. Postgrad. Med.,134(5): 474-479. https://doi.org/10.1080/00325481.2022.2063604
Yang, T., Wang, R., Liu, H., Wang, L., Li, J., Wu, S., Chen, X., Yang, X. and Zhao, Y., 2021. Berberine regulates macrophage polarization through IL-4-STAT6 signaling pathway in Helicobacter pylori-induced chronic atrophic gastritis. Life Sci.,266:118903. https://doi.org/10.1016/j.lfs.2020.118903
Yin, Y., Liang, H., Wei, N. and Zheng, Z., 2022. Prevalence of chronic atrophic gastritis worldwide from 2010 to 2020: an updated systematic review and meta-analysis. Ann.Palliat. Med.,11(12): 3697-3703.https://doi.org/10.21037/apm-21-1464
Yu, H., Wang, H., Pang, H., Sun, Q., Lu, Y., Wang, Q. and Dong, W., 2024. Correlation of chronic atrophic gastritis with gastric-specific circulating biomarkers. Arab J. Gastroenterol.,25(1): 37-41.https://doi.org/10.1016/j.ajg.2023.11.004
Zhang, T., Zhang, B., Xu, J., Ren, S., Huang, S., Shi, Z., Guo, S., Bian, L., Wang, P., Wang, F., Cai, Y. and Tang, X., 2022. Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial. Chin. Med.,17(1): 142. https://doi.org/10.1186/s13020-022-00692-7
Zhang, Y., Li, F., Yuan, F., Zhang, K., Huo, L., Dong, Z., Lang, Y., Zhang, Y., Wang, M., Gao, Z., Qin, Z. and Shen, L., 2020. Diagnosing chronic atrophic gastritis by gastroscopy using artificial intelligence. Dig. Liver Dis.,52(5): 566-572.https://doi.org/10.1016/j.dld.2019.12.146
Zheng, S.Y., Zhu, L., Wu, L.Y., Liu, H.R., Ma, X.P., Li, Q., Wu, M.D., Wang, W.J., Li, J.and Wu, H.G., 2023. Helicobacter pylori-positive chronic atrophic gastritis and cellular senescence. Helicobacter,28(1): e12944. https://doi.org/10.1111/hel.12944
Copyright (c) 2025 Pan Xue
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.